-
1
-
-
77957766128
-
A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma
-
abstract# 4. This positive phase 3 trial showed that ipilimumab alone or combined with immunotherapy resulted in a significant improvement in OS. Ipilimumab trial is open for prostate cancer patients
-
O'Day S, Hodi FS, McDermott DF, et al. A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma. J Clin Oncol 2010, 28:18s: abstract# 4. This positive phase 3 trial showed that ipilimumab alone or combined with immunotherapy resulted in a significant improvement in OS. Ipilimumab trial is open for prostate cancer patients.
-
(2010)
J Clin Oncol
, vol.28
-
-
O'Day, S.1
Hodi, F.S.2
McDermott, D.F.3
-
3
-
-
77955066199
-
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
-
This is the pivotal trial that showed a difference in the median survival as well as immunologic effects in the treated population, including antibody and T cell-specific activity to P2024 and PAP. This has the most definitive dataset
-
Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. NEJM 2010, 5:411-22. This is the pivotal trial that showed a difference in the median survival as well as immunologic effects in the treated population, including antibody and T cell-specific activity to P2024 and PAP. This has the most definitive dataset.
-
(2010)
NEJM
, vol.5
, pp. 411-422
-
-
Kantoff, P.W.1
Higano, C.S.2
Shore, N.D.3
-
4
-
-
33746012881
-
Placebo-controlled phase III trial of immunologic therapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
-
DOI 10.1200/JCO.2005.04.5252
-
Small EJ, Schellhammer PF, Higano CS et al. Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer. J Clin Oncol 2006, 24:3089-94. (Pubitemid 46638945)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.19
, pp. 3089-3094
-
-
Small, E.J.1
Schellhammer, P.F.2
Higano, C.S.3
Redfern, C.H.4
Nemunaitis, J.J.5
Valone, F.H.6
Verjee, S.S.7
Jones, L.A.8
Hershberg, R.M.9
-
5
-
-
68549135290
-
Integrated Data from 2 Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trials of Active Cellular Immunotherapy with Sipuleucel-T in Advanced Prostate Cancer
-
This paper aggregates the data from two phase 3 trials with sipuleucel-T
-
Higano CS, Schellhammer PF, Small EJ, Integrated Data From 2 Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trials of Active Cellular Immunotherapy With Sipuleucel-T in Advanced Prostate Cancer. Cancer 2009,115(16):3670-79. This paper aggregates the data from two phase 3 trials with sipuleucel-T.
-
(2009)
Cancer
, vol.115
, Issue.16
, pp. 3670-3679
-
-
Higano, C.S.1
Schellhammer, P.F.2
Small, E.J.3
-
6
-
-
0034043167
-
Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer
-
Burch PA, Breen JK, Buckner JC, et al. Priming Tissue-specific Cellular Immunity in a Phase I Trial of Autologous Dendritic Cells for Prostate Cancer. Clinical Cancer Research 2000, 6: 2175-82. (Pubitemid 30399182)
-
(2000)
Clinical Cancer Research
, vol.6
, Issue.6
, pp. 2175-2182
-
-
Burch, P.A.1
Breen, J.K.2
Buckner, J.C.3
Gastineau, D.A.4
Kaur, J.A.5
Laus, R.L.6
Padley, D.J.7
Peshwa, M.V.8
Pitot, H.C.9
Richardson, R.L.10
Smits, B.J.11
Sopapan, P.12
Strang, G.13
Valone, F.H.14
Vuk-Pavlovic, S.15
-
7
-
-
77952238610
-
Update: Immunological Strategies for Prostate Cancer
-
This is a recent review of prostate cancer immunotherapy
-
Drake CG, Antonarakis ES. Update: Immunological Strategies for Prostate Cancer. Curr Urol Rep 2010, 11:202-07. This is a recent review of prostate cancer immunotherapy.
-
(2010)
Curr Urol Rep
, vol.11
, pp. 202-207
-
-
Drake, C.G.1
Antonarakis, E.S.2
-
8
-
-
0035164478
-
Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer
-
Almand B, Clark JI, Nikitina E et al. Increase production of immature myeloid cells in cancer patients: a mechanism of immnosuppression in cancer. The Journal of Immunology 2001, 166: 678-89. (Pubitemid 32038493)
-
(2001)
Journal of Immunology
, vol.166
, Issue.1
, pp. 678-689
-
-
Almand, B.1
Clark, J.I.2
Nikitina, E.3
Van Beynen, J.4
English, N.R.5
Knight, S.C.6
Carbone, D.P.7
Gabrilovich, D.I.8
-
9
-
-
70450162100
-
A changing world for DCvax: A PSMA loaded autologous dendritic cell vaccine for prostate cancer
-
Fishman M. A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer. Expert Opin Biol Ther 2009, 9(12):1565-75.
-
(2009)
Expert Opin Biol Ther
, vol.9
, Issue.12
, pp. 1565-1575
-
-
Fishman, M.1
-
10
-
-
3042701410
-
Concordant down-regulation of proto-oncogene PML and major histocompatibility antigen HLA class I expression in high-grade prostate cancer
-
Zhang H, Melamed J, Wei P et al. Concordant down-regulation of proto-oncogene PML and major histocompatibility antigen HLA class I expression in high-grade prostate cancer. Cancer Immunity 2003.3:2
-
(2003)
Cancer Immunity
, vol.3
, pp. 2
-
-
Zhang, H.1
Melamed, J.2
Wei, P.3
-
11
-
-
0028939302
-
Molecular Characterization of Defective Antigen Processing in Human Prostate Cancer
-
Sanda MG, Restifo NP, Walsh JC et al. Molecular Characterization of Defective Antigen Processing in Human Prostate Cancer. J Natl Cancer Inst 1995; 87(4):280-85.
-
(1995)
J Natl Cancer Inst
, vol.87
, Issue.4
, pp. 280-285
-
-
Sanda, M.G.1
Restifo, N.P.2
Walsh, J.C.3
-
12
-
-
70349561448
-
PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model
-
Zhang L, Gajewski TF, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 2009, 114(8): 1545-52.
-
(2009)
Blood
, vol.114
, Issue.8
, pp. 1545-1552
-
-
Zhang, L.1
Gajewski, T.F.2
Kline, J.3
-
13
-
-
70349569569
-
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
-
Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009;114 (8):1537-44.
-
(2009)
Blood
, vol.114
, Issue.8
, pp. 1537-1544
-
-
Ahmadzadeh, M.1
Johnson, L.A.2
Heemskerk, B.3
-
15
-
-
36348989162
-
Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells
-
Nefedova Y, Fishman M, Sherman S, el al. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res. 2007, 67(22):11021-8.
-
(2007)
Cancer Res.
, vol.67
, Issue.22
, pp. 11021-11028
-
-
Nefedova, Y.1
Fishman, M.2
Sherman, S.3
-
16
-
-
63849112500
-
The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: Focus on hematology
-
Curti A, Trabanelli S, Salvestrini V, et al. The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. Blood 2009, 113(11): 2394-2401.
-
(2009)
Blood
, vol.113
, Issue.11
, pp. 2394-2401
-
-
Curti, A.1
Trabanelli, S.2
Salvestrini, V.3
-
17
-
-
33745559710
-
The role of nitric oxide in tumour progression
-
DOI 10.1038/nrc1910, PII N1910
-
Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nature Reviews Cancer 2006, 6:521-534. (Pubitemid 43980541)
-
(2006)
Nature Reviews Cancer
, vol.6
, Issue.7
, pp. 521-534
-
-
Fukumura, D.1
Kashiwagi, S.2
Jain, R.K.3
-
18
-
-
66149142809
-
Endothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasis
-
Lahdenranta J, Hagendoorn J, Padera TP et al. Endothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasis. Cancer Res 2009, 69(7):2801-8.
-
(2009)
Cancer Res
, vol.69
, Issue.7
, pp. 2801-2808
-
-
Lahdenranta, J.1
Hagendoorn, J.2
Padera, T.P.3
-
20
-
-
79955823162
-
Correlation between product parameters and overall survival in 3 trials of Sipuleucel-T, an Autologous Cellular Immunotherapy for the treatment of Prostate Cancer
-
abstract #4552 Presented at This article presents how the difference in quantification of CD54+ dendritic cells in the apheresis product versus the ready-to-ship sipuleucel-T product correlates with overall survival
-
Stewart FP, DelaRosa CP, Sheikh N et al. Correlation between product parameters and overall survival in 3 trials of Sipuleucel-T, an Autologous Cellular Immunotherapy for the treatment of Prostate Cancer. abstract #4552 Presented at ASCO Annual Meeting 2010 Chicago, Illinois; June 4-8, 2010. This article presents how the difference in quantification of CD54+ dendritic cells in the apheresis product versus the ready-to-ship sipuleucel-T product correlates with overall survival.
-
ASCO Annual Meeting 2010 Chicago, Illinois; June 4-8, 2010
-
-
Stewart, F.P.1
DelaRosa, C.P.2
Sheikh, N.3
-
21
-
-
4744337716
-
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
-
DOI 10.1056/NEJMoa041318
-
Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513-20. (Pubitemid 39315318)
-
(2004)
New England Journal of Medicine
, vol.351
, Issue.15
, pp. 1513-1520
-
-
Petrylak, D.P.1
Tangen, C.M.2
Hussain, M.H.A.3
Lara Jr., P.N.4
Jones, J.A.5
Taplin, M.E.6
Burch, P.A.7
Berry, D.8
Moinpour, C.9
Kohli, M.10
Benson, M.C.11
Small, E.J.12
Raghavan, D.13
Crawford, E.D.14
-
22
-
-
38349167518
-
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study
-
Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26(2):242-5.
-
(2008)
J Clin Oncol
, vol.26
, Issue.2
, pp. 242-245
-
-
Berthold, D.R.1
Pond, G.R.2
Soban, F.3
-
23
-
-
4744366279
-
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
-
DOI 10.1056/NEJMoa040720
-
Tannock IF, de Wit R, Berry WR, Horti J et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. NEJM 2004;351(15):1502-12. (Pubitemid 39315317)
-
(2004)
New England Journal of Medicine
, vol.351
, Issue.15
, pp. 1502-1512
-
-
Tannock, I.F.1
De Wit, R.2
Berry, W.R.3
Horti, J.4
Pluzanska, A.5
Chi, K.N.6
Oudard, S.7
Theodore, C.8
James, N.D.9
Turesson, I.10
Rosenthal, M.A.11
Eisenberger, M.A.12
-
24
-
-
0032747375
-
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate- specific antigen working group
-
Bubley GJ, Carducci M, Dahut W, et al. Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17(11): 3461-67. (Pubitemid 29517916)
-
(1999)
Journal of Clinical Oncology
, vol.17
, Issue.11
, pp. 3461-3467
-
-
Bubley, G.J.1
Carducci, M.2
Dahut, W.3
Dawson, N.4
Daliani, D.5
Eisenberger, M.6
Figg, W.D.7
Freidlin, B.8
Halabi, S.9
Hudes, G.10
Hussain, M.11
Kaplan, R.12
Myers, C.13
Oh, W.14
Petrylak, D.P.15
Reed, E.16
Roth, B.17
Sartor, O.18
Scher, H.19
Simons, J.20
Sinibaldi, V.21
Small, E.J.22
Smith, M.R.23
Trump, D.L.24
Vollmer, R.25
Wilding, G.26
more..
-
25
-
-
73949098659
-
Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients with Castrate-Refractory Prostate Cancer Progressing after Prior Chemotherapy: The SPARC Trial
-
Data presented in this trial showed that satraplatin offers PSA response, tumor regression, and improved median time to progression in pretreated patients, but with no OS increment
-
Sternberg CN, Petrylak DP, Sartor O, et al. Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial. J Clin Oncol 2009; 27(32): 5431-5438. Data presented in this trial showed that satraplatin offers PSA response, tumor regression, and improved median time to progression in pretreated patients, but with no OS increment.
-
(2009)
J Clin Oncol
, vol.27
, Issue.32
, pp. 5431-5438
-
-
Sternberg, C.N.1
Petrylak, D.P.2
Sartor, O.3
-
26
-
-
77955714649
-
A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab inmen with metastatic castration-resistant prostate cancer: Survival results of CALGB 90401
-
abstract LBA4511
-
Kelly WK, Halabi S, Carducci MA et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab inmen with metastatic castration-resistant prostate cancer: Survival results of CALGB 90401. J Clin Oncol 2010; 28:18s. abstract LBA4511.
-
(2010)
J Clin Oncol
, vol.28
-
-
Kelly, W.K.1
Halabi, S.2
Carducci, M.A.3
-
27
-
-
33947610197
-
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT investigators
-
DOI 10.1200/JCO.2006.06.8197
-
Beer TM, Ryan CW, Venner PM, et al. Double-Blinded Randomized Study of High-Dose Calcitriol Plus Docetaxel Compared With Placebo Plus Docetaxel in Androgen-Independent Prostate Cancer: A Report From the ASCENT Investigators. J Clin Oncol 2007;25(6):669-74. (Pubitemid 350002922)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.6
, pp. 669-674
-
-
Beer, T.M.1
Ryan, C.W.2
Venner, P.M.3
Petrylak, D.P.4
Chatta, G.S.5
Ruether, J.D.6
Redfern, C.H.7
Fehrenbacher, L.8
Saleh, M.N.9
Waterhouse, D.M.10
Carducci, M.A.11
Vicario, D.12
Dreicer, R.13
Higano, C.S.14
Ahmann, F.R.15
Chi, K.N.16
Henner, W.D.17
Arroyo, A.18
Clow, F.W.19
-
28
-
-
79955068371
-
Docetaxel (D) plus high-dose calcitriol versus D plus prednisone for patients with progressive castration-resistant prostate cancer: Results from the phase III ASCENT2 trial
-
abstract # 4509
-
Scher HI, Chi KN, De Wit R, et al. Docetaxel (D) plus high-dose calcitriol versus D plus prednisone for patients with progressive castration-resistant prostate cancer: Results from the phase III ASCENT2 trial. J Clin Oncol 2010; 28:15s:abstract # 4509.
-
(2010)
J Clin Oncol
, vol.28
-
-
Scher, H.I.1
Chi, K.N.2
De Wit, R.3
-
29
-
-
0034554863
-
Immunotherapy of Hormone-Refractory Prostate Cancer with Antigen-Loaded Dendritic Cells
-
Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of Hormone-Refractory Prostate Cancer With Antigen-Loaded Dendritic Cells. J Clin Oncol 2000;18(23):3894-3903.
-
(2000)
J Clin Oncol
, vol.18
, Issue.23
, pp. 3894-3903
-
-
Small, E.J.1
Fratesi, P.2
Reese, D.M.3
-
30
-
-
71249156207
-
A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer. Abstract LBA150
-
Presented at
-
Higano C, Saad F, Somer B et al. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer. Abstract LBA150. Presented at 2009 Genitourinary Cancers Symposium Orlando, Florida; Feb 26-28, 2009.
-
2009 Genitourinary Cancers Symposium Orlando, Florida; Feb 26-28, 2009
-
-
Higano, C.1
Saad, F.2
Somer, B.3
-
31
-
-
70349926513
-
A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer
-
Abstract 7. Presented at
-
Small E, Demkow T, Gerritsen WR, et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer. Abstract 7. Presented at 2009 Genitourinary Cancers Symposium Orlando, Florida; Feb 26-28,2009.
-
2009 Genitourinary Cancers Symposium Orlando, Florida; Feb 26-28,2009
-
-
Small, E.1
Demkow, T.2
Gerritsen, W.R.3
-
33
-
-
77957682309
-
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomized open-label trial
-
TROPIC Investigators This article shows the clinical antitumor activity and improved overall survival that this new tubulin-binding taxane drug has in CRPC
-
De Bono JS, Oudard S, Ozguroglu M, et al; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet. 2010;376(9747):1147-54. This article shows the clinical antitumor activity and improved overall survival that this new tubulin-binding taxane drug has in CRPC.
-
(2010)
Lancet
, vol.376
, Issue.9747
, pp. 1147-1154
-
-
De Bono, J.S.1
Oudard, S.2
Ozguroglu, M.3
-
34
-
-
70349456786
-
A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu
-
This is an extension of the sipuleucel-T platform to another antigen
-
Peethambaram PP, Melisko ME, Rinn KJ, et al. A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu. Clin Cancer Res. 2009;15(18):5937-44. This is an extension of the sipuleucel-T platform to another antigen.
-
(2009)
Clin Cancer Res
, vol.15
, Issue.18
, pp. 5937-5944
-
-
Peethambaram, P.P.1
Melisko, M.E.2
Rinn, K.J.3
-
35
-
-
46749085802
-
An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: A multicentre, open-label, randomised phase III trial
-
Wood C, Srivastava P, Bukowski R, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet. 2008;372(9633):145-54.
-
(2008)
Lancet
, vol.372
, Issue.9633
, pp. 145-154
-
-
Wood, C.1
Srivastava, P.2
Bukowski, R.3
-
36
-
-
79955846344
-
An adjuvant vaccination with Reniale prolongs survival in patients with renal cell carcinoma following radical nephrectomy: Secondary analysis of a multicenter phase III trial
-
Doehn C, Richter A, Theodor RA, et al. An adjuvant vaccination with Reniale prolongs survival in patients with renal cell carcinoma following radical nephrectomy: secondary analysis of a multicenter phase III trial. European Urology Supplements 2006; 5(2);286.
-
(2006)
European Urology Supplements
, vol.5
, Issue.2
, pp. 286
-
-
Doehn, C.1
Richter, A.2
Theodor, R.A.3
|